Business

Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook. The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter. Ester Baiget, President & CE

articleNovonesis A/s Class BMay 8, 20253/company/novonesis-as-class-b/news/novonesis-delivered-a-strong-q1-with-11percent-organic-growth-and-confirms-full-year-outlook
Novonesis delivered a strong Q1 with 11% organic growth and confirms full-year outlook

About this update from Novonesis A/s Class B

[{"type":"image","alt":"Novonesis (Novozymes A/S)","displaySize":"","headline":null,"caption":"Novonesis (Novozymes A/S)","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":38,"url":"https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/zKklvML9_v1QAJVxEtCwVg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTUzO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/d587064c2241c08df4f2bac0e72e38fb","width":300,"height":38}},"lazy":false},{"type":"text","content":"COPENHAGEN, Denmark – May 8, 2025. The global leader in biosolutions, Novonesis, had a strong start to its financial year with organic sales growth of 11% and an adjusted EBITDA margin of 38.3%. The company maintains the full-year outlook.","length":239,"tagName":"p"},{"type":"text","content":"The sales growth was broad-based across both regions and industries. Emerging markets grew by 15% organically, and developed markets increased by 9%. Across all sales areas, the company delivered double-digit growth in the quarter.","length":231,"tagName":"p"},{"type":"text","content":"Ester Baiget, President & CEO, says:","length":40,"tagName":"p"},{"type":"text","content":"“We started the year with strong sales growth and earnings. This is a testament to our innovative solutions, resilient global business model, and our ability to continue to meet the increasing demand for biosolutions in an ever-changing world.”","length":244,"tagName":"p"},{"type":"text","content":"“Emerging markets were a key growth driver, and all our four sales areas grew by double digits. We’re pleased with our progress, and we maintain our full-year financial outlook.”","length":178,"tagName":"p"},{"type":"text","content":"“Overall, our Q1 performance underscores the value of our solutions in helping customers do more with less—enabling higher yields, improved throughput, enhanced performance, and greater benefits. And it shows that growth and planet stewardship can be two sides of the same coin.”","length":279,"tagName":"p"},{"type":"text","content":"During the first three months of the financial year, Novonesis launched six innovations including an advanced protease portfolio for swift and efficient stain removal.","length":172,"tagName":"p"},{"type":"text","content":"Divisional sales performance organic In the first three ...

More updates from Novonesis A/s Class B

Emerging marketsorganic sales growthsales growthsales areasdouble-digit growthstrong sales growth